Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: Results from a pilot study

Tumori

Volumn 96, Issue 6, 2010, Pages 955-958

  Cao, Christopher ^a   Yan, Tristan D ^a   Morris, David L ^a   Bester, Lourens ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Liver metastasis; Microspheres; Pancreatic carcinoma; Radioembolization; Yttrium 90

Indexed keywords

MICROSPHERE Y 90; RADIOACTIVE MICROSPHERE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MALE; PANCREAS CARCINOMA; PILOT STUDY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RADIOEMBOLIZATION; TREATMENT RESPONSE;

EID: 79551493715     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/548.6515     Document Type: Article

References (17)

1. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, Evans RG: Patterns of failure after curative resection of pancreatic carcinoma. Cancer, 66: 56-61, 1990.
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 15: 2403-2413, 1997.
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25: 1960-1966, 2007.
4. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol, 27: 5513-5518, 2009.
5. Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS: Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: A single-institute study. Oncology, 76: 333-337, 2009.
6. Takada T, Yasuda H, Amano H, Yoshida M, Uchida T: Simultaneous hepatic resection with pancreatoduodenectomy for metastatic pancreatic head carcinoma: Does it improve survival? Hepatogastroenterology, 44: 567-573, 1997.
7. Yamada H, Hirano S, Tanaka E, Shichinohe T, Kondo S: Surgical treatment of liver metastases from pancreatic cancer. Hpb, 8: 85-88, 2006.
8. Ariel IM: Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (y90 radiating microspheres). Ann Surg, 162: 267-278, 1965.
9. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B: Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med, 35: 1637-1644, 1994.
10. Herba MJ, Illescas FF, Thirlwell MP, Boos GJ, Rosenthall L, Atri M, Bret PM: Hepaticmalignancies: Improved treatment with intraarterial y-90. Radiology, 169: 311-314, 1988.
11. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, Sergie Z, Wong CY, Thurston KG: Treatment of unresectable hepatocellular carcinoma with use of 90y microspheres (therasphere): safety, tumor response, and survival. J Vasc Interv Radiol, 16: 1627-1639, 2005.
12. Salem R, Thurston KG: Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 3: Comprehensive literature review and future direction. J Vasc Interv Radiol, 17: 1571-1593, 2006.
13. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL: Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg, 97: 537-543, 2010.
14. 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Intervent Radiol, 17: 1251-1278, 2006.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92: 205-216, 2000.
16. Katsumata K, Tomioka H, Sumi T, Yamasaki T, Takagi M, Kato F, Suzuki Y, Aoki T, Koyanagi Y: Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres. Int J Clin Oncol, 8: 110-112, 2003.
17. Vogl TJ, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U, Scheller A, Zangos S, Heller M: Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol, 132: 745-755, 2006.